PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1147335
PUBLISHER: DelveInsight Business Research LLP | PRODUCT CODE: 1147335
Contact us about how to customize the report with add-on data.
DelveInsight's 'Eosinophilic Esophagitis (EoE) - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of EoE in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The eosinophilic esophagitis (EoE) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted eosinophilic esophagitis (EoE) market size from 2019 to 2032, segmented by 7MM. The report also covers the current eosinophilic esophagitis (EoE) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.
Study period: 2019-2032.
According to the National Organization for Rare Disorders (NORD) and the American Academy of Allergy, Asthma, and Immunology (AAAAI), eosinophilic esophagitis (EoE), also known as "asthma of the esophagus," is defined as a chronic, local immune-mediated disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus, clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The major symptoms include heartburn, regurgitation, esophageal stenosis, and dysphagia, which are more frequent in young adults and children.
The diagnosis of EoE depends on the clinical manifestations and endoscopic and histological findings in esophageal mucosa biopsies. Endoscopic findings in most patients include linear grooves on the esophagus wall, concentric rings, whitish exudates that resemble candidal infection, Schatzki rings, a reduction in the size of the esophagus, and superficial tears of the mucosa after endoscope introduction. A histological diagnosis is confirmed when there are ≥15 eosinophils per high-power field (HPF).
The main aim of the treatment of EoE is not only clinical improvement but also histological improvement to prevent the development of esophageal stricture. In 2020, the American Gastroenterology Association (AGA) and the Joint Task Force on Allergy-Immunology Practice Parameters (JTF) recommended certain guidelines on the management of EoE. The therapeutic approach against EoE consists of the "3D" concept: Diet, drugs, and dilation. The patient is treated based on the severity of their symptoms or endoscopic findings, such as esophageal narrowing or stricture. Histological improvement is generally used as the primary outcome in clinical trials rather than symptomatic improvement due to the difficulty in evaluating the symptoms objectively and uniformly. It is common for these patients to modify their diet or eating behavior to avoid dysphagia or an impaction. PPIs are useful as a first-line treatment for patients with EoE. Corticosteroids are another effective therapy for the treatment of EoE. The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission. IL-4 and IL-13 inhibitors are promising in clinical trials, and recently the Food and Drug Administration (FDA) approved DUPIXENT (dupilumab) to treat EoE in adults and pediatric patients aged 12 and older weighing at least 40 kg (which is about 88 pounds), as the first treatment for EoE. Esophageal endoscopic dilation is most commonly used in adults with established esophageal strictures. According to recent EoE consensus statements and societal guidelines, periodic dilation is considered an acceptable alternative to medical or dietary therapy in some healthy adults with EoE.
It covers the details of conventional and current medical therapies and diagnoses available in the eosinophilic esophagitis (EoE) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The eosinophilic esophagitis (EoE) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.
The disease epidemiology covered in the report provides historical and forecasted eosinophilic esophagitis (EoE) epidemiology segmented as the diagnosed prevalent cases of eosinophilic esophagitis (EoE), age-specific cases of eosinophilic esophagitis (EoE), and gender-specific cases of eosinophilic esophagitis (EoE). The report includes the diagnosed prevalent eosinophilic esophagitis (EoE) scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the eosinophilic esophagitis (EoE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed prevalent patient population of eosinophilic esophagitis (EoE) in the 7MM countries was more than 700,000 cases in 2021.
As per the estimates, the US had the highest patient population of eosinophilic esophagitis (EoE) in 2021. Among the EU5 countries, Germany had the highest diagnosed patient population of eosinophilic esophagitis (EoE), with approximately 58,000 cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed prevalent patient population of eosinophilic esophagitis (EoE), with nearly 33,000 cases in 2021.
The drug chapter segment of the eosinophilic esophagitis (EoE) report encloses the detailed analysis of eosinophilic esophagitis (EoE) marketed drugs and late-stage (Phase III, Phase II/III, and Phase II) pipeline drugs. It also helps understand the eosinophilic esophagitis (EoE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The current standard of care with swallowed corticosteroid are related to well-known adverse effects (especially in the pediatric population) and there is not enough long-term data to confirm that they can reverse the remodeling process of the esophageal mucosa. Additionally, the topical treatment in the upper gastrointestinal tract is tremendously difficult due to ultra-short esophageal transit times of less than 2 s from the mouth to the stomach. A few clinical studies have systematically evaluated the use of monoclonal antibodies in EoE.
Thus, there is an urgent need to identify new and existing medications that are potentially safe and effective for EoE patients and evaluate those therapies using appropriate clinical trials.
Drug developers are gradually shifting their attention toward eosinophilic esophagitis (EoE) to meet the patient pool's current demands and counter the unmet needs of the therapeutic market.
Several companies are working robustly on many new therapies, such as cendakimab (BMS), benralizumab (AstraZeneca), estrasimod (Pfizer), ESO-101 (ESOCAP), lirentelimab (Allakos), APT-1011 (Ellodi Pharmaceutical).
Cendakimab/RPC4046/CC-93538 (BMS) is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results, and currently, the company is conducting two Phase III clinical studies to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.
APT-1011 (Ellodi Pharmaceutical), a novel, oral formulation of fluticasone incorporating Adare's proprietary AdvaTab technology, allows for topical delivery of the drug to the esophagus whilst minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 effectively reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. APT-1011 has received ODD from the FDA and EMA and FDT from FDA. It is currently in Phase III development (FLUTE II), following the successful completion of its Phase II study (FLUTE I) in 2019.
The eosinophilic esophagitis (EoE) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted eosinophilic esophagitis (EoE) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the eosinophilic esophagitis (EoE) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
As per DelveInsight, the eosinophilic esophagitis (EoE) market in 7MM is expected to change in 2019-2032.
This section includes a glimpse of the eosinophilic esophagitis (EoE) market in 7MM. In the 7MM, the eosinophilic esophagitis (EoE) market size was approximately USD 600 million in 2021.
This section provides the total eosinophilic esophagitis (EoE) market size. It also provides the market size of eosinophilic esophagitis (EoE) by therapies in the United States.
The United States accounts for the highest market size of eosinophilic esophagitis (EoE) than the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section provides the total eosinophilic esophagitis (EoE) market size. It also provides eosinophilic esophagitis (EoE) market size by therapies in Germany, France, Italy, Spain, and the United Kingdom.
This section provides the total eosinophilic esophagitis (EoE) market size. It also provides the market size of eosinophilic esophagitis (EoE) by therapies in Japan.
This section focuses on the uptake rate of potential drugs launched or expected to be launched in the market during 2019-2032. The analysis covers eosinophilic esophagitis (EoE) market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyses eosinophilic esophagitis (EoE)'s key players in developing targeted therapeutics.
Major players include: Bristol Myers Squibb, Ellodi Pharmaceuticals, and AstraZeneca whose key products are expected to get launched in the US market by 20XX.
The report covers collaborations, acquisitions, mergers, licensing, and patent details for emerging eosinophilic esophagitis (EoE) therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the eosinophilic esophagitis (EoE) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging treatment patterns or eosinophilic esophagitis (EoE) market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform a competitive and market intelligence analysis of the eosinophilic esophagitis (EoE) market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.